US$ 21.44
new glp-1 drug Eli Lilly to seek approval of weight-loss this year Amazon's New GLP‑1 Service Promises
Description
Inagaki N, Seino Y, Takeda J, et al

Bays, P

doi: 10.1056/NEJMoa2301972, PMID: [DOI] [PubMed] [Google Scholar] 106
:max_bytes(150000):strip_icc()/Wegovy-pill-pic-590ed53ed3304ba8b2388f9d78886dae.png)
However, 12% are not sure which type they take

Given that obesity is a major modifiable risk factor for OSAS, and that the pathogenesis of OSAS involves metabolic dysregulation, systemic inflammation, and abnormal adipose tissue distribution, tirzepatide may offer multidimensional therapeutic benefits in this context (26)
Obesity and cancer
